BridgeBio Pharma (BBIO) Profit After Tax (2018 - 2026)
BridgeBio Pharma (BBIO) reported Profit After Tax of -$166.6 million for Q1 2026, up 1.8% on a YoY basis from -$163.6 million in Q1 2025, and up 14.43% sequentially from -$194.6 million in Q4 2025.
BridgeBio Pharma (BBIO) Profit After Tax (2018 - 2026) Analysis & Trends
BridgeBio Pharma (BBIO) has 9 years of Profit After Tax data on file, last reported at -$166.6 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax rose 1.8% year-over-year to -$166.6 million; the trailing twelve-month figure through Mar 2026 stood at -$729.9 million (down 7.84% YoY), and the FY2025 full-year result was -$732.9 million, down 34.89% from the prior year.
- Profit After Tax advanced to -$166.6 million in Q1 2026, from -$194.6 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$2.6 million in Q2 2022 to a low of -$267.4 million in Q4 2024.
- A 5-year average of -$151.8 million and a median of -$166.6 million in 2026 frame the typical range for Profit After Tax.
- Across the five-year window, Profit After Tax surged 97.49% in 2022 and sank 6179.91% in 2023, its largest moves.
- Tracing BBIO's Profit After Tax over 5 years: stood at -$140.6 million in 2022, then slipped by 21.17% to -$170.3 million in 2023, then tumbled by 56.98% to -$267.4 million in 2024, then increased by 27.21% to -$194.6 million in 2025, then increased by 14.43% to -$166.6 million in 2026.
- Business Quant data shows BBIO's Profit After Tax at -$166.6 million in Q1 2026, -$194.6 million in Q4 2025, and -$184.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | BridgeBio Pharma | 16.15 Bn | 15.22 Bn | 184.58 Mn | -166.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -166.56 Mn |
| Dec 31, 2025 | -194.64 Mn |
| Sep 30, 2025 | -184.94 Mn |
| Jun 30, 2025 | -183.76 Mn |
| Mar 31, 2025 | -169.61 Mn |
| Dec 31, 2024 | -267.39 Mn |
| Sep 30, 2024 | -164.25 Mn |
| Jun 30, 2024 | -75.54 Mn |
| Mar 31, 2024 | -36.16 Mn |
| Dec 31, 2023 | -170.33 Mn |
| Sep 30, 2023 | -179.49 Mn |
| Jun 30, 2023 | -160.70 Mn |
| Mar 31, 2023 | -142.73 Mn |
| Dec 31, 2022 | -140.57 Mn |
| Sep 30, 2022 | -140.19 Mn |
| Jun 30, 2022 | -2.56 Mn |
| Mar 31, 2022 | -201.33 Mn |
| Dec 31, 2021 | -152.28 Mn |
| Sep 30, 2021 | -161.02 Mn |
| Jun 30, 2021 | -102.07 Mn |